Policy Practices to Maximise Social Benefit from Biosimilars

Inotai A^1,2*, Csanádi M^1,3, Vitezic D⁴, Francetic I⁵, Tesar T⁶, Bochenek T⁷, Lorenzovici L^8,9, Dylst P¹⁰ and Kaló Z^1,2

¹Syreon Research Institute, Budapest, Hungary

²Center for Expert Medicine, Zagreb, Croatia

³Department of Pharmaceutics and Central Clinical Pharmacy, University of Pécs, Pécs, Hungary

⁴University of Rijeka School of Medicine and University Hospital Centre Rijeka, Rijeka, Croatia

⁵Center for Expert Medicine, Zagreb, Croatia

⁶Department of Organisation and Management in Pharmacy, Comenius University in Bratislava, Bratislava, Slovakia

⁷Department of Drug Management, Institute of Public Health, Jagiellonian University Medical College, Krakow, Poland

⁸Syreon Research Romania, Tirgu Mures, Romania

⁹Faculty of Technical and Human Sciences, Sapientia University, Tirgu Mures, Romania

¹⁰Biosimilar Medicines Group, Medicines for Europe, Brussels, Belgium